172. The United Kingdom is committed to implementing Article 66.2 of the TRIPS Agreement to promote and encourage technology transfer to least developed country Members. We will provide an update on two projects undertaken by the United Kingdom in recent years.
173. The project Geo-Referenced Infrastructure and Demographic Data for Development (GRID3) aims to transform the ability of governments, the private sector, development organisations and civil society to use geospatial and demographic data for effective planning and implementation of key services.
174. GRID3 is working in Nigeria, Zambia, Mozambique, South Sudan and Democratic Republic of Congo and has conducted scoping missions to Tanzania, Ethiopia, Cameroon, Sierra Leone, Ghana, Burkina Faso, Mali and Niger.
175. The lack of basic information such as population distribution, population structure, settlement maps, road networks, water bodies or administrative boundaries means that decisions such as where to target relief efforts, position polling stations and health centres, how to allocate resources at the subnational level or where to expand energy and internet access are based on out of date and incomplete information.
176. GRID3 has helped create and use high-resolution demographic data to address identified data needs, providing better local estimates of population which can be used to plan and deliver services and to identify populations which may not otherwise be identified.
177. Another example is the United Kingdom's support to Product Development Research. This project aims to develop new human health technologies, such as diagnostics, drugs and vaccines, and to ensure that they are acceptable, affordable and available to those that need them in low income countries.
178. The United Kingdom Government provides support to a number of different organisations including product development public private product development partnerships (PDPs), which are not for profit organisations based in a number of different countries, working with partners across the globe, depending on the disease and type of technology being developed.
179. PDP investments have resulted in critically important products, including a new paediatric fixed dose TB drug, with over one million treatments distributed in 93 countries since its launch in 2016, as well as the development of two new vaccines to treat rotavirus for use in India.
180. The United Kingdom is happy to discuss its projects in more detail with Members at a later date.